" class="no-js "lang="en-US"> Stéphane Bancel - Medtech Alert
Tuesday, April 22, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Stephane Bancel

Stéphane Bancel

About Stéphane Bancel

Related Story

Appointments

 James Mock Joins Moderna as Chief Financial Officer | Pharmtech Focus

James Mock Joins Moderna as Chief Financial Officer

August 19 2022

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

COVID-19

 Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-containing Bivalent Booster in the UK | Pharmtech Focus

Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-containing Bivalent Booster in the UK

August 17 2022

Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

COVID-19

 Moderna and the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-containing Bivalent Candidates; EC Purchases Additional 15 Million Doses | Pharmtech Focus

Moderna and the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-containing Bivalent Candidates; EC Purchases Additional 15 Million Doses

August 11 2022

Moderna, Inc.(NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an […]

COVID-19

 EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union | Pharmtech Focus

EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union

July 26 2022

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that […]

Diseases

 Moderna's Omicron-containing Bivalent Booster Candidate

Moderna's Omicron-containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared to Currently Authorized Booster

July 14 2022

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Clinical Trials

 Moderna Announces First Participant Dosed in a Phase 1 Trial of Its Nipah Virus mRNA Vaccine

Moderna Announces First Participant Dosed in a Phase 1 Trial of Its Nipah Virus mRNA Vaccine, mRNA-1215

July 14 2022

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Clinical Trials

 Moderna Announces Bivalent Booster mRNA -1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants Ba.4 and Ba.5 | Pharmtech Focus

Moderna Announces Bivalent Booster mRNA -1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants Ba.4 and Ba.5

June 24 2022

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

COVID-19

 Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom | Pharmtech Focus

Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom

June 22 2022

Moderna, Inc . (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

COVID-19

 Moderna Announces Omicron-containing Bivalent Booster Candidate Mrna-1273.214 Demonstrates Superior Antibody Response Against Omicron | Pharmtech Focus

Moderna Announces Omicron-containing Bivalent Booster Candidate Mrna-1273.214 Demonstrates Superior Antibody Response Against Omicron

June 10 2022

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

COVID-19

 Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day | Pharmtech Focus

Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day

May 19 2022

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messengerRNA (mRNA) therapeutics and vaccines, today announced new […]

Appointments

 Arpa Garay Joins Moderna as Chief Commercial Officer | Pharmtech Focus

Arpa Garay Joins Moderna as Chief Commercial Officer

April 28 2022

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

COVID-19

 Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023 | Pharmtech Focus

Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023

December 3 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]

COVID-19

 Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant | Pharmtech Focus

Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

November 29 2021

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

COVID-19

 Moderna Announces EU and EEA Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to Help End COVID-19 Pandemic in Low Income Countries | Pharmtech Focus

Moderna Announces EU and EEA Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to Help End COVID-19 Pandemic in Low Income Countries

November 16 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

COVID-19

 Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022 | Pharmtech Focus

Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022

October 14 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

COVID-19

 Moderna to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year | Pharmtech Focus

Moderna to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year

October 8 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

COVID-19

 Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older | Pharmtech Focus

Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older

October 6 2021

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today […]

Drug Development

 Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada | Pharmtech Focus

Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada

August 11 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Appointments

 Dr. Paul Burton to Join Moderna as Chief Medical Officer | Pharmtech Focus

Dr. Paul Burton to Join Moderna as Chief Medical Officer

June 15 2021

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]

COVID-19

 Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union | Pharmtech Focus

Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union

June 8 2021

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]

COVID-19

 UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility | Pharmtech Focus

UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility

June 2 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and UNICEF today announced […]

Clinical Trials

 Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June | Pharmtech Focus

Moderna Announces TeenCOVE Study of COVID-19 Vaccine (mRNA-1273) in Adolescents Meets Primary Endpoint

May 27 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

COVID-19

 Moderna Announces New Supply Agreement with Australia for 25 Million Doses of its COVID-19 Vaccine | Pharmtech Focus

Moderna Announces New Supply Agreement with Australia for 25 Million Doses of its COVID-19 Vaccine

May 13 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

COVID-19

 Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022 and Option for Additional 7 Million Doses | Pharmtech Focus

Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022 and Option for Additional 7 Million Doses

May 6 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Manufacturing

 Moderna Announces Expansion of its Manufacturing Technology Center in Massachusetts | Pharmtech Focus

Moderna Expands Manufacturing Technology Center

May 5 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]

COVID-19

 Moderna New Supply Agreement with Israel for 2022 | Pharmtech Focus

Moderna New Supply Agreement with Israel for 2022

April 21 2021

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a […]

COVID-19

 Moderna announces FDA Authorization of Moderna COVID-19 vaccine in U.S. | Pharmtech Focus

Moderna announces FDA Authorization of Moderna COVID-19 vaccine in U.S.

December 18 2020

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that […]